Stroke recurrence in children with sickle cell disease treated with hydroxyurea following first clinical stroke

American Journal of Hematology

Volumn 86, Issue 10, 2011, Pages 846-850

  Ali, Susanna Bortolusso ^a   Moosang, Michelle ^a   King, Lesley ^a   Knight Madden, Jennifer ^a   Reid, Marvin ^a  

^a UNIVERSITY OF THE WEST INDIES   (Jamaica)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYUREA;

ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; COHORT ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; CONFIDENCE INTERVAL; FEMALE; HAZARD RATIO; HEMIPARESIS; HUMAN; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; PHYSICAL DISABILITY; PRIORITY JOURNAL; RECURRENT DISEASE; SICKLE CELL ANEMIA; SPECIAL EDUCATION; STROKE;

ANEMIA, SICKLE CELL; CHILD; COHORT STUDIES; FEMALE; HUMANS; HYDROXYUREA; MALE; RECURRENCE; STROKE;

EID: 80052907324     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.22142     Document Type: Article

References (39)

1. Platt OS, Brambilla DJ, Rosse WF, et al. Mortality in sickle cell disease-Life expectancy and risk factors for early death. N Engl J Med 1994; 330: 1639-1644.
2. Bardakdjian-Michau J, Bahuau M, Hurtrel D, et al. Neonatal screening for sickle cell disease in France. J Clin Pathol 2009; 62: 31-33.
3. Pereira MM, Vives Corrons J-L. Neonatal haemoglobinopathy screening in Spain. J Clin Pathol 2009; 62: 22-25.
4. Streetly A, Latinovic R, Hall K, Henthorn J. Implementation of universal newborn bloodspot screening for sickle cell disease and other clinically significant haemoglobinopathies in England: Screening results for 2005-7. J Clin Pathol 2009; 62: 26-30.
5. Brousseau DC, Panepinto JA, Nimmer M, Hoffmann RG. The number of people with sickle-cell disease in the United States: National and state estimates. Am J Hematol; 85: 77-78.
6. King L, Fraser R, Forbes M, et al. Newborn sickle-cell disease screening: The Jamaican experience (1995-2006). J Med Screen 2007; 14: 117-122.
7. Gaston MH, Verter JI, Woods G, et al. Prophylaxis with oral penicillin in children with sickle cell anemia. N Engl J Med 1986; 314: 1593-1599.
8. Serjeant GR, Serjeant BE. Management of sickle cell disease; Lessons from the Jamaican cohort study. Blood Rev 1993; 7: 137-145.
9. Ohene-Frempong K, Weiner SJ, Sleeper LA, et al. The cooperative study of sickle cell disease. Cerebrovascular accidents in sickle cell disease: Rates and risk factors. Blood 1998; 91: 288-294.
10. Balkaran B, Char G, Morris JS, et al. Stroke in a cohort of patients with homozygous sickle cell disease. J Pediatr 1992; 120: 360-366.
11. Powars D, Wilson B, Imbus C, et al. The natural history of stroke in sickle cell disease. Am J Med 1978; 65: 461-471.
12. Russell M, Goldberg H, Hodson A, et al. Effect of transfusion therapy on arteriographic abnormalities and on recurrence of stroke in sickle cell disease. Blood 1984; 63: 162-169.
13. Scothorn D, Price C, Schwartz D, et al. Risk of recurrent stroke in children with sickle cell disease receiving blood transfusion therapy for at least five years after initial stroke. J Paediatr 2002; 140: 348-354.
14. Pegelow CH, Adams RJ, McKie V, et al. Risk of recurrent stroke in patients with sickle cell disease treated with erythrocyte transfusions. J Paediatr 1995; 126: 896-899.
15. Sarnaik S, Soorya D, Kim J, et al. Periodic transfusions for sickle cell anemia and CNS infarction. Am J Dis Child 1979; 133: 1254-1257.
16. Sarnaik S, Lusher J. Neurological complications of sickle cell anemia. Am J Pediatr Hematol Oncol 1982; 4: 386-394.
17. Bernaudin F, Verlhac S, Arnaud C, et al. Impact of early transcranial Doppler screening and intensive therapy on cerebral vasculopathy outcome in a newborn sickle cell anemia cohort. Blood 2011; 117: 1130-1140.
18. Sumoza A, Bisotti Rd, Sumoza D, Fairbanks V. Hydroxyurea (HU) for prevention of recurrent stroke in sickle cell anemia (SCA). Am J Hematol 2002; 71: 161-165.
19. Ware R, Zimmerman S, Schultz W. Hydroxyurea as an alternative to blood transfusions for the prevention of recurrent stroke in children with sickle cell disease. Blood 1999; 94: 3022-3026.
20. Vichinsky EP, Luban NL, Wright E, et al. Prospective RBC phenotype matching in a stroke-prevention trial in sickle cell anemia: A multicenter transfusion trial. Transfusion 2001; 41: 1086-1092.
21. Rosse WF, Gallagher D, Kinney TR, et al. Transfusion and alloimmunization in sickle cell disease. The cooperative study of sickle cell disease. Blood 1990; 76: 1431-1437.
22. Castellino SM, Combs MR, Zimmerman SA, et al. Erythrocyte autoantibodies in paediatric patients with sickle cell disease receiving transfusion therapy: Frequency, characteristics and significance. Br J Haematol 1999; 104: 189-194.
23. Harmatz P, Butensky E, Quirolo K, et al. Severity of iron overload in patients with sickle cell disease receiving chronic red blood cell transfusion therapy. Blood 2000; 96: 76-79.
24. Delea TE, Hagiwara M, Thomas SK, et al. Outcomes, utilization, and costs among thalassemia and sickle cell disease patients receiving deferoxamine therapy in the United States. Am J Hematol 2008; 83: 263-270.
25. Wayne AS, Schoenike SE, Pengelow CH. Financial analysis of chronic transfusion for stroke prevention in sickle cell disease. Blood 2000; 96: 2379-2372.
26. Adams RJ, Brambilla D, STOP2-Trial-Investigators. Discontinuing prophylactic transfusions used to prevent stroke in sickle cell disease. N Engl J Med 2005; 353: 2769-2778.
27. Ferster A, Tahriri P, Vermylen C, et al. Five years of experience with hydroxyurea in children and young adults with sickle cell disease. Blood 2001; 97: 3628-3632.
28. Kinney TR, Helms RW, O'Branski EE, et al. Safety of hydroxyurea in children with sickle cell anemia: Results of the HUG-KIDS study, A phase I/II trial. Blood 1999; 94: 1550-1554.
29. Ware RE. How I use hydroxyurea to treat young patients with sickle cell anemia. Blood 2010; 115: 5300-5311.
30. Dobson SR, Holden KR, Nietert PJ, et al. Moyamoya syndrome in childhood sickle cell disease: A predictive factor for recurrent cerebrovascular events. Blood 2002; 99: 3144-3150.
31. Olnes M, Chi A, Haney C, et al. Improvement in hemolysis and pulmonary arterial systolic pressure in adult patients with sickle cell disease during treatment with hydroxyurea. Am J Hematol 2009; 84: 529-531.
32. Helton KJ, Wang WC, Wynn LW, et al. The effect of hydroxyurea on vasculopathy in a child with sickle cell disease. Am J Neuroradiol 2002; 23: 1692-1696.
33. Ware RE, Steinberg MH, Kinney TR. Hydroxyurea: An alternative to transfusion therapy for stroke in sickle cell anemia. Am J Hematol 1995; 50: 140-143.
34. Ware RE, Zimmerman SA, Sylvestre PB, et al. Prevention of secondary stroke and resolution of transfusional iron overload in children with sickle cell anemia using hydroxyurea and phlebotomy. J Paediatr 2004; 145: 346-352.
35. National Institutes of Health. Stroke prevention study in children with sickle cell anemia, Iron overload stopped early. Available at:. Accessed May 10, 2011.
36. Zimmerman SA, Schultz WH, Burgett S, et al. Hydroxyurea therapy lowers transcranial Doppler flow velocities in children with sickle cell anemia. Blood 2007; 110: 1043-1047.
37. Lefèvre N, Dufour D, Gulbis B, et al. Use of hydroxyurea in prevention of stroke in children with sickle cell disease. Blood 2008; 111: 963-964.
38. Hankins JS, Fortner GL, McCarville MB, et al. The natural history of conditional transcranial Doppler flow velocities in children with sickle cell anaemia. Br J Haematol 2008; 142: 94-99.
39. Gulbis B, Haberman D, Dufour D, et al. Hydroxyurea for sickle cell disease in children and for prevention of cerebrovascular events: The Belgian experience. Blood 2005; 105: 2685-2690.